QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

← catalyst calendar

NCT03228667 · readout in 1,108 d

Sponsored by ImmunityBio, Inc. (industry) · IBRX — their whole pipeline →.

Phase

Phase 2

Status

Active, not recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

40estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2018-12-11

actual

When the study began enrolling

Primary completion

2029-08-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2030-12-31

estimated

The whole study's end, after follow-up

First posted

2017-07-25

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-01-14

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Urothelial Carcinoma
Head and Neck Squamous Cell Carcinoma
Merkel Cell Carcinoma
Melanoma
Renal Cell Carcinoma
Gastric Cancer
Cervical Cancer
Hepatocellular Carcinoma
Microsatellite Instability
Mismatch Repair Deficiency
Colorectal Cancer

Interventions

Drug: N-803 + Pembrolizumab
Drug: N-803 + Nivolumab
Drug: N-803 + Atezolizumab
Drug: N-803 + Avelumab
Drug: N-803 + Durvalumab
Drug: N-803 + Pembrolizumab + PD-L1 t-haNK
Drug: N-803 + Nivolumab + PD-L1 t-haNK
Drug: N-803 + Atezolizumab + PD-L1 t-haNK
Drug: N-803 + Avelumab + PD-L1 t-haNK
Drug: N-803 + Durvalumab + PD-L1 t-haNK
Drug: N-803 + Docetaxel + Pembrolizumab
Drug: N-803 + Docetaxel + Nivolumab

Primary outcomes

what the primary-completion date above is the date OF

ORR, defined as Investigator-assessed CR + PR per RECIST v1.1.

measured Evaluated from the first dose of study drug and repeated at each scheduled disease-assessment visit for up to 24 months (or until progression/death), with the time-to-response summarized using Kaplan-Meier methods

Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ

measured Measured from the date of the first study-drug administration to the date of death (any cause) and followed for up to 24 months after the last dose (or until death), allowing the correlation with on-treatment ALC changes

Permalink · IBRX's whole pipeline · Catalyst calendar · Every registered study · What changed